- In February 2026, Acadia Healthcare Company reported fourth-quarter 2025 revenue of US$821.46 million but recorded a net loss of US$1.18 billion, largely driven by a US$996.20 million non-cash goodwill impairment, even as full-year 2025 sales reached US$3.31 billion.
- Despite the large impairment-driven loss, management issued 2026 revenue guidance of US$3.37 billion to US$3.45 billion and flagged a modest 0%–1% same-facility volume range, highlighting how policy changes in New York Medicaid and occupancy trends may meaningfully influence operational performance.
- Against this backdrop, we’ll examine how the sizable non-cash goodwill impairment and cautious 2026 revenue outlook reshape Acadia Healthcare’s investment narrative.
Find 50 companies with promising cash flow potential yet trading below their fair value.
Acadia Healthcare Company Investment Narrative Recap
To own Acadia Healthcare, you need to believe that demand for behavioral health services and payer support can ultimately outweigh near term Medicaid and facility level challenges. The Q4 results and US$996.20 million goodwill impairment sharpen the focus on two things: execution on occupancy improvements as the key near term catalyst, and policy driven Medicaid pressure as the biggest current risk. The impairment itself is non cash, but it underlines how sensitive the story is to reimbursement shifts.
The clearest link to this investment debate is management’s 2026 guidance for US$3.37 billion to US$3.45 billion of revenue and just 0% to 1% same facility volume growth. That outlook directly reflects both the planned occupancy ramp at newer facilities and the estimated 350 basis point headwind tied to New York Medicaid policy changes impacting certain Pennsylvania specialty sites. For investors focused on catalysts, how Acadia performs against this guidance now sits at the center of the thesis.
Read the full narrative on Acadia Healthcare Company (it's free!)
Acadia Healthcare Company's narrative projects $4.1 billion revenue and $322.9 million earnings by 2028. This requires 8.3% yearly revenue growth and about a $183.7 million earnings increase from $139.2 million today.
Uncover how Acadia Healthcare Company's forecasts yield a $22.29 fair value, a 13% downside to its current price.
Exploring Other Perspectives
Yet for investors, the real question is how exposed Acadia remains to shifting Medicaid policies and supplemental payments that could materially affect...
Before this impairment driven loss, the most optimistic analysts were penciling in faster growth, with revenue reaching about US$4.2 billion and earnings of roughly US$368 million by 2028, while also assuming that underperforming facilities would stop dragging on EBITDA. This new set of results and guidance may prompt you to reconsider whether that upbeat path still feels realistic, or whether the risk of further facility level pressures deserves more weight.
Explore 4 other fair value estimates on Acadia Healthcare Company - why the stock might be worth less than half the current price!
Reach Your Own Conclusion
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Acadia Healthcare Company research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
- Our free Acadia Healthcare Company research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Acadia Healthcare Company's overall financial health at a glance.
Seeking Other Investments?
Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:
- Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
- We've uncovered the 16 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
- The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com